Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
- PMID: 19200817
- DOI: 10.1016/j.vaccine.2009.01.071
Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
Abstract
Therapeutic vaccination against cancer-associated antigens represents an attractive option for cancer therapy in view of its potential efficacy, the possibility of long-lasting immunity against the cancer, and safety profile. Cancer patients are however usually immunosuppressed and most cancer-associated antigens are 'self-antigens', making it a significant challenge to vaccinate patients against a cancer-associated antigen. Various immunostimulant adjuvants are therefore under investigation in an effort to boost the immune system to overcome the tolerance to tumour associated self-antigens and the ambient immunosuppressory influence of cytokines and regulatory T-cells (Tregs). Many adjuvants appear to be specific ligands for toll-like receptors (TLR) which are potent activators of innate immune responses [Kwissa M, Kasturi SP, Pulendran B. Expert Rev Vaccines. The Science of Adjuvants 2007 6(October(5)):673-84] [1], activating dendritic cell (DC) maturation and inflammatory cytokine secretion, inducing an increase in the cross talk between the innate and adaptive immune systems, and thereby driving the expansion of CTLs that can destroy cancer cells. However, recently some TLR agonists such as CpG have been shown to generate parallel immunosuppressive and inflammatory responses in innate immune cells capable of induction and expansion of Tregs [Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008 27(January 7(2)):168-80 [2]; Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008;27(2):218-24] [3]. In this context it is noteworthy that poly(I:C), a synthetic double-stranded RNA polymer and a TLR3 agonist, has been shown in mouse models to be capable of enhancing the T cell response to nonimmunogenic self-antigen linked dendritic cell based vaccine strategy, and stimulating diabetic insulitis in the presence of Tregs [Hornum L, Lundsgaard D, Markholst H. PolyI:C induction of diabetes is controlled by Iddm4 in rats with a full regulatory T cell pool. Ann N Y Acad Sci 2007;1110:65-72] [4]. Ampligen poly(I:C(12)U) is a GMP-grade synthetic analogue of poly(I:C) and therefore suitable for human use. Its effects in a preclinical setting have been recently tested to be similar to poly(I:C) [Hornum L, Lundsgaard D, Markholst H. PolyI:C induction of diabetes is controlled by Iddm4 in rats with a full regulatory T cell pool. Ann N Y Acad Sci 2007;1110:65-72]. In particular, it potently induces in vitro maturation of human monocyte derived DC with sustained bioactive IL12 production. In addition human monocyte derived DC primed with tumour lysate and matured with Ampligen are capable of generating Th1 specific anti-cancer responses in peripheral blood T-cells derived from cancer patients in the presence of ascites medium containing immunosuppressory cytokines. In this review the key findings are summarised and discussed with a view to offering a rationale for the use of Ampligen as a potentially safe adjuvant capable of overcoming the tumour-related immune tolerance mechanisms in a clinical setting.
Similar articles
-
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.Oncogene. 2008 Jan 7;27(2):168-80. doi: 10.1038/sj.onc.1210910. Oncogene. 2008. PMID: 18176598 Review.
-
A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.Vaccine. 2009 Jan 1;27(1):107-15. doi: 10.1016/j.vaccine.2008.10.024. Epub 2008 Oct 31. Vaccine. 2009. PMID: 18977262
-
Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.Hum Immunol. 2007 Oct;68(10):813-22. doi: 10.1016/j.humimm.2007.08.001. Epub 2007 Aug 29. Hum Immunol. 2007. PMID: 17961769
-
Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.Int Immunol. 2008 Jan;20(1):1-9. doi: 10.1093/intimm/dxm112. Epub 2007 Nov 1. Int Immunol. 2008. PMID: 17981792
-
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.Adv Drug Deliv Rev. 2013 Oct;65(10):1386-99. doi: 10.1016/j.addr.2013.05.013. Epub 2013 Jun 7. Adv Drug Deliv Rev. 2013. PMID: 23751781 Review.
Cited by
-
Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer.Sci Rep. 2023 Nov 9;13(1):19440. doi: 10.1038/s41598-023-46254-1. Sci Rep. 2023. PMID: 37945630 Free PMC article.
-
Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.Front Immunol. 2023 Oct 23;14:1227833. doi: 10.3389/fimmu.2023.1227833. eCollection 2023. Front Immunol. 2023. PMID: 37936697 Free PMC article. Review.
-
Toll‑like receptor 3 ligands for breast cancer therapies (Review).Mol Clin Oncol. 2023 Jun 22;19(2):60. doi: 10.3892/mco.2023.2656. eCollection 2023 Aug. Mol Clin Oncol. 2023. PMID: 37424627 Free PMC article. Review.
-
TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization.Microb Cell. 2023 Apr 19;10(6):117-132. doi: 10.15698/mic2023.06.797. eCollection 2023 Jun 5. Microb Cell. 2023. PMID: 37275475 Free PMC article.
-
Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection.Prog Mol Subcell Biol. 2022;61:145-189. doi: 10.1007/978-3-031-01237-2_7. Prog Mol Subcell Biol. 2022. PMID: 35697940
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources